文献速递间质性肺疾病慢阻肺

定量间质异常进展与COPDGene及PLuSS队列结局

Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts.
PubMed 文献 · Chest · 2022-06-30

研究评估4635名COPDGene队列和1307名PLuSS队列参与者两次访视间定量间质异常进展,发现年龄、女性、现吸烟及MUC5B次要等位基因与进展相关;进展与FVC和6分钟步行距离下降及死亡率增加相关。

要点

  • 年龄、女性、现吸烟及MUC5B次要等位基因与定量间质异常进展相关。
  • 定量间质异常年增长百分比与FVC年下降及6分钟步行距离下降相关。
  • 定量间质异常进展与死亡率增加相关,COPDGene风险比1.69,PLuSS风险比1.28。

核心结论

  • 定量间质异常的纵向客观测量可能有助于识别不良事件风险最高且最可能从早期干预中获益的人群。

研究设计与样本

  • 评估COPDGene队列4635名参与者和PLuSS队列1307名参与者访视1至访视2间的定量间质异常进展。
  • 采用多变量线性回归确定进展危险因素及其与FVC和6分钟步行距离的纵向关联,采用Cox回归分析与死亡率的关联。

主要发现

  • 入组年龄、女性、现吸烟状态和MUC5B次要等位基因与定量间质异常进展相关。
  • 定量间质异常年增长每百分比与FVC年下降相关:COPDGene为8.5 mL/y(95% CI,4.7-12.4 mL/y;P < .001);PLuSS为9.5 mL/y(95% CI,3.7-15.4 mL/y;P = .001)。
  • 定量间质异常年增长每百分比与6分钟步行距离下降相关。
  • 定量间质异常年增长每百分比与死亡率增加相关:COPDGene风险比1.69(95% CI,1.34-2.12;P < .001);PLuSS风险比1.28(95% CI,1.10-1.49;P = .001)。

临床怎么用

  • 对具有年龄、女性、现吸烟或MUC5B次要等位基因等风险因素者,可考虑纵向定量监测间质异常进展。
  • 定量间质异常进展者应关注肺功能、运动能力和死亡风险,考虑早期干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk factors and clinical outcomes of quantitative interstitial abnormality progression over time have not been characterized. RESEARCH QUESTIONS: What are the associations of quantitative interstitial abnormality progression with lung function, exercise capacity, and mortality? What are the demographic and genetic risk factors for quantitative interstitial abnormality progression? STUDY DESIGN AND METHODS: Quantitative interstitial abnormality progression between visits 1 and 2 was assessed from 4,635 participants in the Genetic Epidemiology of COPD (COPDGene) cohort and 1,307 participants in the Pittsburgh Lung Screening Study (PLuSS) cohort. We used multivariable linear regression to determine the risk factors for progression and the longitudinal associations between progression and FVC and 6-min walk distance, and Cox regression models for the association with mortality. RESULTS: Age at enrollment, female sex, current smoking status, and the MUC5B minor allele were associated with quantitative interstitial abnormality progression. Each percent annual increase in quantitative interstitial abnormalities was associated with annual declines in FVC (COPDGene: 8.5 mL/y; 95% CI, 4.7-12.4 mL/y; P < .001; PLuSS: 9.5 mL/y; 95% CI, 3.7-15.4 mL/y; P = .001) and 6-min walk distance, and increased mortality (COPDGene: hazard ratio, 1.69; 95% CI, 1.34-2.12; P < .001; PLuSS: hazard ratio, 1.28; 95% CI, 1.10-1.49; P = .001). INTERPRETATION: The objective, longitudinal measurement of quantitative interstitial abnormalities may help identify people at greatest risk for adverse events and most likely to benefit from early intervention.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Choi B, Adan N, Doyle TJ, et al. Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts. Chest. 2022. PMID: 35780812. doi:10.1016/j.chest.2022.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。